Liver News and Research

RSS

Researchers solve long-standing mystery behind dormant disseminated breast tumor cells

The long-standing mystery behind dormant disseminated breast tumor cells and what activates them after years and even decades of latency may have been solved. Researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) have identified the microenvironment surrounding microvasculature - the small blood vessels that transport blood within tissues - as a niche where dormant cancer cells reside. When these blood vessels begin to sprout, the new tips produce molecules that transform dormant cancer cells into metastatic tumors.

4 Jun 2013

CWRU nursing school receives NINR grant to support palliative care

Medical advancements that extend the lives of patients with cancer, heart failure and other serious chronic diseases have created another need: more clinicians skilled in specialized care for people with terminal illnesses.

4 Jun 2013

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene are likely to fare better if treated with a targeted therapy than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.

3 Jun 2013

Researchers solve two longstanding challenges in liver tissue engineering

Prometheus, the mythological figure who stole fire from the gods, was punished for this theft by being bound to a rock. Each day, an eagle swept down and fed on his liver, which then grew back to be eaten again the next day.

3 Jun 2013

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.

3 Jun 2013

Researchers develop RNA aptamers that inhibit HCV replication

Treatments against hepatitis C virus have only been partially successful. A major problem is that antivirals generate drug resistance. Now Seong-Wook Lee of Dankook University, Yongin, Republic of Korea and his collaborators have developed agents that bind to the business end of a critical protein, disabling it so successfully that no resistance has arisen.

3 Jun 2013

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

A new partnership, first of its kind for both organizations, will see Roswell Park Cancer Institute and Jasco Pharmaceuticals, LLC collaborating to advance development of an investigational pharmacological therapy that shows promise for treating both solid-tumor cancers and hematologic malignancies.

1 Jun 2013

New hope for children with multi-system LCH

A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis can achieve survival rates as high as 84 percent-a full 15 percent improvement over the previous clinical trial in this series.

30 May 2013

Spherical nanoparticles transform into netlike structures at site of cancer

Scientists at the University of California, San Diego, have designed tiny spherical particles to float easily through the bloodstream after injection, then assemble into a durable scaffold within diseased tissue. An enzyme produced by a specific type of tumor can trigger the transformation of the spheres into netlike structures that accumulate at the site of a cancer, the team reports in the journal Advanced Materials this week.

29 May 2013

Synthetic compound derived from sea anemone toxin shows potential to treat obesity

Scientists at UC Irvine reported this week that a synthetic compound ShK-186, originally derived from a sea anemone toxin, has been found to enhance metabolic activity and shows potential as a treatment for obesity and insulin resistance.

28 May 2013

Children with Type 2 diabetes are at high risk to develop heart, kidney and eye problems

The news about youth and diabetes keeps getting worse. The latest data from the national TODAY diabetes study shows that children who develop Type 2 diabetes are at high risk to develop heart, kidney and eye problems faster and at a higher rate than people who acquire Type 2 diabetes as adults.

26 May 2013

Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition associated with liver disease.

24 May 2013

Research: Anti-cancer drug tested as possible treatment for Alzheimer's disease proved ineffective

An anti-cancer drug about to be tested in a clinical trial by a biomedical company in Ohio as a possible treatment for Alzheimer's disease has failed to work with the same type of brain plaques that plague Alzheimer's patients, according to results of a study by University of Florida researchers.

24 May 2013

Potential new treatment approaches for liver diseases

By discovering the new mechanism by which estrogen suppresses lipid synthesis in the liver, UC Irvine endocrinologists have revealed a potential new approach toward treating certain liver diseases.

24 May 2013

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced that it has initiated dosing in a Phase I study of SB 9200, its investigational, once daily, oral therapy for the treatment of HCV infection.

24 May 2013

Researchers develop new guidelines to govern amount of blood ordered for surgical patients

Johns Hopkins researchers have developed new guidelines - the first in more than 35 years - to govern the amount of blood ordered for surgical patients.

23 May 2013

New drug delivery system can help treat lung cancer

Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.

23 May 2013

AASLD members at forefront to raise awareness of hepatitis B and C

Viral hepatitis is an asymptomatic disease affecting more than 5.3 million Americans. More than 75 percent of those with hepatitis C are unaware they have the virus.

23 May 2013

Experts urge baby boomers to get screened for HCV

If you're a baby boomer, you may not know that odds are high that you're carrying the hepatitis C virus, putting yourself at risk for illness that can range from minor to life threatening.

22 May 2013

Gilead Sciences' sofosbuvir MAA gets EMA validation

Gilead Sciences, Inc. today announced that the company's Marketing Authorisation Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus infection, which was submitted to the European Medicines Agency on April 17, 2013, has been fully validated and is now under assessment.

22 May 2013

Liver News and Research

Researchers solve long-standing mystery behind dormant disseminated breast tumor cells

CWRU nursing school receives NINR grant to support palliative care

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

Researchers solve two longstanding challenges in liver tissue engineering

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

Researchers develop RNA aptamers that inhibit HCV replication

RPCI, Jasco Pharmaceuticals partner to advance development of cancer therapy

New hope for children with multi-system LCH

Spherical nanoparticles transform into netlike structures at site of cancer

Synthetic compound derived from sea anemone toxin shows potential to treat obesity

Children with Type 2 diabetes are at high risk to develop heart, kidney and eye problems

Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

Research: Anti-cancer drug tested as possible treatment for Alzheimer's disease proved ineffective

Potential new treatment approaches for liver diseases

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

Researchers develop new guidelines to govern amount of blood ordered for surgical patients

New drug delivery system can help treat lung cancer

AASLD members at forefront to raise awareness of hepatitis B and C

Experts urge baby boomers to get screened for HCV

Gilead Sciences' sofosbuvir MAA gets EMA validation

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News